November 1, 2018 / 6:47 AM / 17 days ago

Novo Nordisk Q3 profit slightly below forecast, nudges up 2018 sales outlook

COPENHAGEN, Nov 1 (Reuters) - Denmark’s Novo Nordisk , the world’s top maker of diabetes drugs, posted third-quarter operating profit slightly below forecasts on Thursday, but lifted the lower end of its sales forecast for the year.

The firm posted a quarterly operating profit of 11.81 billion Danish crowns ($1.80 billion), below an average 11.93 billion crowns forecast in a Reuters poll of analysts. .

The firm narrowed its 2018 sales growth forecast to 4-5 percent from previously 3-5 percent and kept its operating profit growth outlook at 2-5 percent, both measured in local currencies. ($1 = 6.5768 Danish crowns) (Reporting by Stine Jacobsen; Editing by Jacob Gronholt-Pedersen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below